Bioglutide
NA-931 | Quadruple IGF-1/GLP-1/GIP/Glucagon Agonist
Bioglutide (NA-931) is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. Developed by Biomed Industries, this small molecule derived from a cyclic IGF-1 fragment demonstrates remarkable oral bioavailability and blood-brain barrier penetration. Phase 2 clinical trials showed up to 13.8% body weight reduction in 13 weeks while preserving muscle mass - a significant advantage over existing GLP-1 therapies. Currently in Phase 2b/3 trials for obesity and type 2 diabetes.
Daily dose
50-150mg
Frequency
Once daily (oral)
Cycle length
12+ weeks
Storage
Room temp
Key benefits
First-in-class oral quadruple agonist, significant weight loss (up to 13.8%), muscle mass preservation, milder GI side effects than injectable GLP-1s, once-daily oral dosing without food restrictions, comprehensive metabolic improvement.
How it works
NA-931 simultaneously activates four metabolic hormone receptors: IGF-1 (promotes muscle preservation and insulin sensitivity), GLP-1 (appetite suppression, insulin secretion, gastric emptying), GIP (glucose metabolism, lipid handling), and glucagon (energy expenditure, fat oxidation). Small lipophilic structure allows oral bioavailability and blood-brain barrier penetration for direct CNS appetite control.
Dosage protocols
Goal
Clinical trial dosing
Dose
50-150mg · Once daily
Route
Oral
Goal
Research starting dose
Dose
2.5-10mg · Once daily
Route
Oral (titrate up)
Research indications
weight Loss
diabetes
metabolic
Administration
Interactions
Safety notes
Investigational drug - not FDA approved
Start low dose, titrate as tolerated
GI side effects typically mild (nausea, diarrhea)
No muscle loss observed in trials
Avoid combining with other GLP-1 agonists
Monitor for pancreatitis symptoms
Drug interactions not fully characterized
Research studies
Phase 2 Clinical Trial - Obesity (2024)
Humans | 125 patients | Oral 50-150mg daily | 13 weeks | 13.8% weight loss at max dose
Randomized, double-blind, placebo-controlled Phase 2 trial (NCT06564753). NA-931 showed dose-dependent weight loss up to 13.8% at 150mg daily. 72% of treated subjects achieved ≥12% weight loss vs 2% placebo. No muscle loss observed, distinguishing from existing therapies.
View study →Phase 1 Trial - Safety and PK (2024)
Humans | 74 patients | Oral dosing | 28 days + 12-week extension | Safety/tolerability
First-in-human study in overweight/obese subjects and T2DM patients. Demonstrated excellent safety profile with maximum 6.4% weight loss in 4 weeks. Blood levels consistent regardless of fasting or fed state. No serious adverse events reported.
View study →EASD 2025 Presentation - Phase 2 Results
Humans | 125 patients | Oral 150mg daily | 13 weeks | 14.8% max weight reduction
Presented at EASD Vienna 2025. Maximum body weight reduction of 14.8% (13.2% placebo-adjusted). 83% of GI adverse events were mild or insignificant. Treatment-emergent adverse events predominantly mild. Supports progression to Phase 3.
View study →ADA 2025 Presentation - Metabolic Effects
Humans | Phase 2 data | Oral dosing | Glucose and lipid improvements
Breakthrough results presented at American Diabetes Association 2025. Demonstrated significant improvements in glycemic control alongside weight loss. Muscle-sparing fat loss attributed to IGF-1 receptor activation.
View study →Preclinical DIO Mouse Study
Mice | Diet-induced obesity model | 14 days | 26% body weight reduction
In vivo study in obese mice showed 26% body weight reduction with no muscle wasting. Fasting glucose reduced 23%, plasma triglycerides dropped 34%, liver fat content fell 46%. Increased energy expenditure and fatty acid oxidation observed.
View study →